No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer’s disease

S Reeves
January 2010
Journal of Neurology, Neurosurgery & Psychiatry;Jan2010, Vol. 81 Issue 1, p119
Academic Journal
OBJECTIVE: Work in experimental animals suggests that an interaction with dopaminergic networks might explain some of the therapeutic effects of the cholinesterase inhibitor class of drugs. This study aimed to test whether acute (single 5 mg) or 4–8 weeks (5–10 mg) of treatment with oral donepezil would elicit measurable striatal dopamine (DA) release in patients with mild to moderate Alzheimer’s disease. A second aim was to establish whether any increase in DA levels would be associated with improvements in cognitive and motor function. METHODS: Percentage change in [11C]-raclopride (RAC) binding potential (BPND) between baseline and treatment conditions was used to provide a measure of DA release. Repeated measures ANOVA was used to determine the effect of treatment on [11C]-RAC BPNDand neuropsychological test performance. RESULTS: Contrary to our prediction there was no significant change in [11C]- RAC BPNDafter acute or a mean of 6 weeks (range 4–12) of treatment with donepezil. Although motor speed (finger tapping) improved following 4–12 weeks of treatment with donepezil (F1,19= 8.7, p = 0.009), this was not associated with the degree of change in [11C]-RAC BPND. CONCLUSIONS: Our findings provide no evidence that striatal DA levels are altered during the first 3 months of donepezil treatment. However, we cannot rule out the possibility that extrastriatal effects may be occurring.


Related Articles

  • Novartis' Exelon shown to reduces behavioral disturbances associated with Alzheimer's disease.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p6 

    Looks into the effect of cholinesterase inhibitor Exelon on the behavioral symptoms associated with Alzheimer's disease. Problems posed by behavioral symptoms in Alzheimer's disease patients; Effects of Exelon on neuropsychiatric and behavioral disturbances seen in patients with Alzheimer's...

  • Reality orientation therapy, given simultaneously with cholinesterase inhibitors, makes the drug more effective.  // Canadian Nursing Home;Oct2004, Vol. 15 Issue 3, p29 

    Provides information on a study on the administration of the reality orientation therapy with cholinesterase inhibitor drugs in Alzheimer's disease patients. Benefits of the combined therapies; Study methods; Findings.

  • Outcome of Alzheimer's Disease: Potential Impact of Cholinesterase Inhibitors. Gillette-Guyonnet, Sophie; Andrieu, Sandrine; Cortes, Frédéric; Nourhashemi, Fati; Cantet, Christelle; Ousset, Pierre-Jean; Reynish, Emma; Grandjean, Hélène; Vellas, Bruno // Journals of Gerontology Series A: Biological Sciences & Medical ;May2006, Vol. 61 Issue 5, p516 

    Background. Alzheimer's disease is fast becoming a major public health concern with serious economic consequences. The cholinesterase inhibitors (CEIs) offer some benefit in the symptomatic treatment of the disease. This study aims to investigate the effect of CEIs on three clinically relevant...

  • Guidelines for the Appropriate Use of Cholinesterase Inhibitors in Patients with Alzheimer's Disease. Schachter, A.S.; Davis, K.L. // CNS Drugs;1999, Vol. 11 Issue 4, p281 

    The cholinesterase inhibitors are the only available scientifically proven symptomatic treatments for dementia of the Alzheimer's type. The guidelines we present summarise the current updated knowledge on the available drugs, including tacrine, donepezil, rivastigmine, metrifonate and...

  • Defining Treatment Response to Donepezil in AlzheimerÂ’s Disease: Responder Analysis of Patient-Level Data from Randomized, Placebo-Controlled Studies. Burns, Alistair; Yeates, Andrew; Akintade, Latif; del Valle, Megan; Zhang, Richard Y.; Schwam, Elias M.; Perdomo, Carlos A. // Drugs & Aging;2008, Vol. 25 Issue 8, p707 

    BACKGROUND: Defining treatment success in progressive diseases, such as Alzheimer’s disease (AD), can be challenging. OBJECTIVE: To explore the impact of employing different criteria to define a treatment ‘responder’ using analyses of patient-level data from randomized,...

  • Memantine Plus Donepezil for Alzheimer's Disease. Slawson, David // American Family Physician;5/1/2004, Vol. 69 Issue 9, p2195 

    Discusses whether the combination of memantine and donepezil is effective in the treatment of Alzheimer's disease. Details of a study comparing the effectiveness of these two drugs; Conclusion that the combination of memantine and donepezil appears to be more beneficial in the treatment of...

  • galantamine.  // Royal Society of Medicine: Medicines;2002, p261 

    The article presents information on galantamine. The drug is an anticholinesterase recently introduced for the symptomatic treatment of mild to moderate dementia of Alzheimer's disease. It is thought only to slow the rate of cognitive deterioration in about half of patients treated. Authorities...

  • Cholinesterase Inhibitors in Alzheimer's Disease: Are they Worth the Cost? Whitehouse, P.J. // CNS Drugs;1999, Vol. 11 Issue 3, p167 

    Several cholinesterase inhibitors have demonstrated their ability to improve cognition in Alzheimer's disease. This paper reviews issues important to determining whether cholinesterase inhibitors are worth their cost. Establishing therapeutic goals in Alzheimer's disease and assessing initial...

  • Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease. Connelly, P. J.; Prentice, N. P.; Fowler, K. G. // Journal of Neurology, Neurosurgery & Psychiatry;Mar2005, Vol. 76 Issue 3, p320 

    Objective: To investigate the possibility that response to cholinesterase inhibitor therapy could be predicted by easily measurable variables that are known to change as a result of treatment (such as the Mini Mental State Examination), measures of function (such as the instrumental activities...


Read the Article


Sign out of this library

Other Topics